(Q45330539)

13 December 2017

Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus (English)

1 reference

13 December 2017

1

Jan van Lunzen

1 reference

13 December 2017

17

Dorothee von Laer

1 reference

13 December 2017

Tobias Glaunsinger

2

1 reference

13 December 2017

Ingrid Stahmer

3

1 reference

13 December 2017

Volker von Baehr

4

1 reference

13 December 2017

Christopher Baum

5

1 reference

13 December 2017

Andrea Schilz

6

1 reference

13 December 2017

Klaus Kuehlcke

7

1 reference

13 December 2017

Sonja Naundorf

8

1 reference

13 December 2017

Holger Martinius

9

1 reference

13 December 2017

Felix Hermann

10

1 reference

13 December 2017

Tsanan Giroglou

11

1 reference

13 December 2017

Sebastian Newrzela

12

1 reference

13 December 2017

Ingrid Müller

13

1 reference

13 December 2017

Francis Brauer

14

1 reference

13 December 2017

Gunda Brandenburg

15

1 reference

13 December 2017

Alexander Alexandrov

16

1 reference

13 December 2017

language of work or name

1 reference

1 May 2007

1 reference

13 December 2017

1 reference

13 December 2017

15

1 reference

13 December 2017

5

1 reference

13 December 2017

1024-1033

1 reference

Antiretroviral-drug resistance among patients recently infected with HIV.

13 December 2017

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Gene therapy for HIV infection: what does it need to make it work?

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Gene transfer in humans using a conditionally replicating lentiviral vector

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Side effects of retroviral gene transfer into hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Membrane-anchored peptide inhibits human immunodeficiency virus entry

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Impact of gene-modified T cells on HIV infection dynamics

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Gene therapy: therapeutic gene causing lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Approaches to gene therapy for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Optimization of retroviral vector generation for clinical application

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Virtual DNA analysis--a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Nomenclature for factors of the HLA system, 2004

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

1 reference

https://api.crossref.org/works/10.1038%2FMT.SJ.6300124

7 January 2021

Identifiers

DOI

10.1038/MT.SJ.6300124

1 reference

13 December 2017

1 reference